For Adverse Cytogenetic Multiple Myeloma, Pom-Dex Active, Well-Tolerated
the Cancer Therapy Advisor take:
According to a new study published in the journal Blood, researchers have found that pomalidomide plus low dose dexamethasone is active and well tolerated in patients with end stage relapsed/refractory multiple myeloma and adverse cytogenetics.
A previous study showed that the drug combination could be safely administered to patients with end stage relapsed/refractory multiple myeloma, but researchers observed a shorter median progression-free survival and overall survival among those with deletion 17p and translocation (4;14).
Therefore, researchers sought to investigate whether patients with adverse cytogenetics would obtain greater benefit if they were to receive pomalidomide plus dexamethasone earlier than in the previous study.
For this study, 50 patients with a median age of 63 years received the drug combination. Results showed that time to progression was 7.3 months for those with t(4;14) and 2.8 months for those with del(17p). In addition, duration of response was 8.3 and 2.4 months for t(4;14) and del(17p), respectively, and the objective response rate was 32% compared with 15%, respectively.
Overall survival was also prolonged, mostly in patients with t(4;14). The researchers note that future studies are warranted to better understand the mechanism of pomalidomide-dexamethasone activity in those with del(17p).
Pomalidomide plus low dose dexamethasone is active and well tolerated in relapsed/refractory multiple myeloma.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Patient-Reported Outcomes in Oncology Expected to Make Regulatory Waves
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- FDA Provides Update on Breast Implant-Associated Anaplastic Large Cell Lymphoma
- Investigational Antiandrogen Drug Delays Metastasis in CRPC
- Q&A With Mark B. Gerstein, PhD, on Diagnostic Genomic vs Exomic Sequencing
- Tivozanib Offers Superior Outcomes in Refractory Metastatic Renal Cell Carcinoma
- First-Line Pembrolizumab Shows Promise in Non-Clear Cell RCC
- Early Tumor Shrinkage With Cabozantinib Improves Survival in Renal Cell Carcinoma
- Combo Superior to Sunitinib in Advanced Renal Cell Carcinoma
- Nivolumab-Ipilimumab Survival Benefit in Advanced RCC Confirmed